See more : Shanghai Conant Optical Co., Ltd. (2276.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Salarius Pharmaceuticals, Inc. (SLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Salarius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Fortinet, Inc. (FTNT) Income Statement Analysis – Financial Results
- DGNV N.V. (DPA.AS) Income Statement Analysis – Financial Results
- Dongwoon Anatech Co., Ltd. (094170.KQ) Income Statement Analysis – Financial Results
- Australian Vintage Ltd (AVG.AX) Income Statement Analysis – Financial Results
- RSWM Limited (RSWM.NS) Income Statement Analysis – Financial Results
Salarius Pharmaceuticals, Inc. (SLRX)
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.84M | 5.23M | 3.47M | 838.00K | 1.28M | 1.01M | 0.00 |
| Cost of Revenue | 10.05K | 6.68K | 19.18K | 6.91K | 4.02K | 431.00K | 507.00K | 663.00K | 49.88K |
| Gross Profit | -10.05K | -6.68K | 1.82M | 5.23M | 3.46M | 407.00K | 768.00K | 348.00K | -49.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 98.96% | 99.87% | 99.88% | 48.57% | 60.24% | 34.42% | 0.00% |
| Research & Development | 7.17K | 15.84M | 8.55M | 6.91M | 4.02M | 11.91M | 16.99M | 20.38M | 12.75M |
| General & Administrative | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 2.35M | 1.37M | 797.49K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.22M | 17.14M | 19.06M | 0.00 |
| SG&A | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 10.57M | 18.50M | 19.86M | 16.46M |
| Other Expenses | 0.00 | 8.87M | -4.00 | -178.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.48M | 35.49M | 40.23M | 29.21M |
| Cost & Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.91M | 36.00M | 40.90M | 29.21M |
| Interest Income | 352.25K | 218.73 | 0.00 | 0.00 | 15.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.05K | 6.68K | 19.18K | 18.06K | 16.93K | 16.95K | 324.55K | 277.23K | 49.88K |
| EBITDA | -12.88K | -31.60M | -12.75M | -7.33M | -6.92M | -22.07M | -34.11M | -39.89M | -29.09M |
| EBITDA Ratio | 0.00% | 0.00% | -698.70% | -149.97% | -272.69% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Operating Income | -12.89K | -31.84M | -12.81M | -7.79M | -9.58M | -22.07M | -34.73M | -39.89M | -29.21M |
| Operating Income Ratio | 0.00% | 0.00% | -696.27% | -148.78% | -276.37% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Total Other Income/Expenses | 352.25 | 233.18K | 44.69K | 434.09K | 1.33M | 152.01K | 291.96K | 393.11K | 72.00K |
| Income Before Tax | -12.54K | -31.61M | -12.77M | -7.35M | -6.94M | -21.92M | -34.43M | -39.49M | -29.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | -693.84% | -140.49% | -200.23% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| Income Tax Expense | 0.00 | -233.18K | -63.88K | -255.50K | -1.33M | 152.01K | -324.58K | -277.12K | -49.85K |
| Net Income | -12.54K | -31.37M | -12.70M | -7.10M | -5.61M | -21.92M | -34.43M | -39.49M | -29.14M |
| Net Income Ratio | 0.00% | 0.00% | -690.37% | -135.61% | -161.88% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| EPS | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| EPS Diluted | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| Weighted Avg Shares Out | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
| Weighted Avg Shares Out (Dil) | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat's Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Penny Stocks On Robinhood For You May 2021 Watch List
Source: https://incomestatements.info
Category: Stock Reports